A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
LY3471851 is a potential first-in-class therapeutic that may address an underlying immune system imbalance in people with many autoimmune conditions. It targets the interleukin (IL-2) receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells. By activating these cells, LY3471851 may act to bring the immune system back into balance.
Inclusion Criteria:
Exclusion Criteria:
CABA, Buenos Aires 1111, Argentina
Ciudad Autónoma de Buenos Aire, Buenos Aires 1417, Argentina
CABA, Ciudad Autónoma de Buenos Aire 1406, Argentina
CABA, Ciudad Autónoma de Buenos Aire C1430EGF, Argentina
SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
Ciudad Autónoma de Buenos Aire, C1221ADC, Argentina
Kiel, 24105, Germany
Hyderabad, Andhra Pradesh 500003, India
Visakhapatanam, Andhra Pradesh 530002, India
Ramat Gan, Central District 5262100, Israel